FDA
-
-
-
-
-
-
-
'Our Top Pick Is Beam Therapeutics Inc (BEAM)'; PT Raised at Bernstein
-
-
-
-
-
-
-
Beam Therapeutics receives FDA RMAT designation for BEAM-101 therapy
-
-
-
-
-
-
-
Beam (BEAM) Announces U.S. FDA RMAT Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency
-
-
-
-
-
-
-
Jones Trading Upgrades Beam Therapeutics Inc (BEAM) to Buy
-
-
-
-
-
-
-
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Beam Therapeutics Inc. (BEAM) said FDA lifts clinical hold on BEAM-201 IND
-
-
-
-
-
-
-
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

